Core Viewpoint - The company has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for RMB 12.396 million, enhancing its strategic control over the regional high-end medical testing services in Southwest China [1] Group 1: Transaction Details - Wuhan Kangshengda has successfully won the bid for a 40% stake in Huaxi Kangshengda through the North Exchange public listing process [1] - The transaction was formalized on November 25, 2025, with a total consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the Southwest region, covering Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient and consistent execution of the overall strategy in the Southwest region [1] - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergistic effects between ICL-driven IVD product development and IVD service upgrades [1] Group 3: Management and Collaboration - The company will take full control over the management appointments, performance assessments, and resource allocation of Huaxi Kangshengda, improving the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the Southwest region [1] - This integration will strengthen the regional operational capabilities of the company [1]